Skip to main content
SpringerLink
Log in

Afatinib

Lack of efficacy: 37 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Mountzios G, et al. An observational study to assess the molecular epidemiology and direct medical costs of epidermal growth factor receptor (Egfr) mutations in patients with advanced egfr mutation-positive non-small cell lung cancer treated with afatinib in real-world clinical settings in Greece. Lung Cancer: Targets and Therapy 12: 93-102, Jan 2021. Available from: URL: https://www.dovepress.com/getfile.php?fileID=73144

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib. Reactions Weekly 1905, 20 (2022). https://doi.org/10.1007/s40278-022-14410-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-14410-5

Search

Navigation